Skip to content

A prospective randomised study of the optimal time for the administration of human chorionic gonadotropin (HCG) in women undergoing IVF in a gonadotropin releasing hormone (GnRH) antagonist cycle

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN36416379
Enrollment
Unknown
Registered
2003-09-12
Start date
2002-07-31
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth: In vitro fertilisation (IVF) Pregnancy and Childbirth Procreative management

Interventions

Randomised controlled trial, Random allocation to receive HCG injection at: 1. Standard time delay 2. 24 h delay 3. 48 h delay

Sponsors

Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients undergoing their first or second cycle of IVF or IVF/intracytoplasmic sperm injection (ICSI). 2. Age of partner 19-36 years. 3. Body mass index 20-30 kg/m2. 4. Serum follicle-stimulating hormone (FSH) concentration in normal range.

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

MeasureTime frame
The main objective is to determine whether there is an optimal time to give HCG injection, and also to observe any differences in the number of eggs being collected, fertilisation rates, embryos quality and pregnancy rates among the three groups.

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026